REGN vs SYK
REGN: Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic areas. SYK: A diversified medical technology leader offering surgical equipment, orthopedic robotics, and minimally invasive neurovascular products that collectively serve over 150 million patients annually across 61 countries.
Side-by-side fundamentals
| Metric | REGN | SYK | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $667.95 | $327.11 | |
| Market cap as of 2026-07-10 | $69.9B | $126.0B | |
| P/E as of 2026-07-10 | 15.80 | 37.74 | REGN lower |
| PEG as of 2026-07-10 | 1.01 | 3.29 | REGN lower |
| Net margin as of 2026-07-10 | +29.6% | +13.2% | REGN higher |
| Gross margin as of 2026-07-10 | +85.7% | +64.2% | REGN higher |
| Operating margin as of 2026-07-10 | +24.3% | +19.7% | REGN higher |
| ROE as of 2026-07-10 | +14.3% | +15.1% | SYK higher |
| ROA as of 2026-07-10 | +11.1% | +7.1% | REGN higher |
| Debt / equity as of 2026-07-10 | 0.09 | 0.64 | REGN lower |
| Revenue growth (YoY) as of 2026-07-10 | +5.9% | +8.8% | SYK higher |
| Revenue CAGR (3y) SEC XBRL | +5.6% | +10.8% | SYK higher |
| Dividend yield as of 2026-07-10 | +0.6% | +1.1% | SYK higher |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-10 | 0.21 | 0.78 | |
| 1-year return as of 2026-07-09 close | +20.9% | -16.6% | REGN higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.